ASCO 2019: Breakfast Brief – Head and neck cancer
PD DDr. Sacha Rothschild, University Hospital Basel, comments on this year’s head and neck cancer studies, as well as lung cancer trials.
Video Contents00:00 KEYNOTE-048: Results support pembrolizumab and pembrolizumab + platinum + 5-FU for defined patients with recurrent metastatic HNSCC. 04:34 No benefit for the TPEx regime compared to standard therapy. 05:03 Ado-trastuzumab emtansine is highly efficacious in patients with HER2 amplified salivary gland cancers. 06:24 JIPANG: Pemetrexed/cisplatin shows similar efficacy compared to vinorelbine/cisplatin with better tolerability than adjuvant chemotherapy for completely resected stage II-IIIA non-squamous non-small-cell lung cancer. 07:38 LCMC3: Neoadjuvant atezolizumab in resectable NSCLC was well tolerated, and pCR and major pathologic response rates are encouraging 08:48 NEOSTAR: The study investigates neoadjuvant nivolumab or nivolumab plus ipilimumab on major pathologic response rates in resectable non-small-cell lung cancer 10:51 Lurbinectidin monotherapy shows promise as a second line treatment in SCLC.
More from this topic:
ASCO 2019: Durable responses in patients with melanoma brain metastases with nivolumab/ipilimumab
11. 06. 2019
ASCO 2019: Pembrolizumab facilitates previously unmet 5-year-overall survival for NSCLC
06. 06. 2019